Close
28/05/2015
Synchrotron light applications for the pharmaceutical industry
More than forty people from the pharmaceutical sector attended the workshop organised by the ALBA Synchrotron on May 7.

Researchers from the MSPD, CLAESS, XALOC, NCD and MISTRAL ALBA beam lines have shown the available state-of-the-art techniques and the advantages that they offer in this field: fast data acquisition and shorter experiments, cost savings and, in the case of X-ray microscopy, suppression of ethical conflicts because this technique can be a previous step before clinical essays with animals and persons.

The companies Enantia and Almirall, which have already collaborated with the ALBA Synchrotron, have commented their own experiences at the facility. Enantia, specialised in research solutions for other companies, has detailed different examples. For Almirall, the analysis of polymorphic compounds – performed at ALBA – has increased its quality control, verifying and quantifying purity grades.

News based on the press release issued by the ALBA synchrotron.

Image: ALBA synchrotron. Structure of a herpesvirus nuclease-antiviral complex. Data collected at the Xaloc beam line (Bongarzone, S., Nadal, M. & Coll, M., IBMB)

More news

06/04/2018 Stradivarius Counts On Omnichannel and Aitana Ocaña 21/03/2018 Sun and salt: SENER’s know-how 15/03/2018 Major Upgrade of an ALBA Synchrotron Beamline 01/03/2018 ALBA Synchrotron is as good at humanities as at sciences! 23/02/2018 Catalonia, 2018/19 Top Southern European Region for FDI Strategy 15/02/2018 ICMAB traps sunlight with superabsorbent nanomaterials
11 12 13 14 15 16 17 18 19 20 21